The Pipeline™ Vantage Embolization Device with Shield Technology™ is used to treat intracranial aneurysms (IA), which are bulges in blood vessels in the brain. This study is designed to check the safety and effectiveness of this device. It is a prospective, multi-center, single-arm clinical study, meaning it looks forward to gathering data from multiple locations and involves patients who will all receive the same kind of treatment without a comparison group. To join, patients must have an intracranial aneurysm and agree to follow the study rules. They cannot participate if they have any health reasons that make the treatment unsafe, are unable to complete follow-ups, or if they're pregnant or breastfeeding. Key Points:

• The study is open to adults with intracranial aneurysms.
• Participants must commit to follow-up visits to collect data.
• Health conditions or other studies might exclude some people from participating.